This announcement is a separate document:
派林生物：北京市嘉源律师事务所关于派斯双林生物制药股份有限公司2020年股票期权与限制性股票激励计划相关价格调整的法律意见书
Pailin Biotech: Legal opinion from Beijing Jiayuan Law Firm on price adjustments related to Paisu Shuanglin Biopharmaceutical Co., Ltd.\'s 2020 stock options and restricted stock incentive plan
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.